Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study (Q36091191)

12 August 2017

title

Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study (English)

1 reference

12 August 2017

3

Jóhannes Reynisson

1 reference

12 August 2017

Feng Zhu

1

1 reference

12 August 2017

Gerard Logan

series ordinal

2

1 reference

12 August 2017

publication date

14 November 2012

1 reference

12 August 2017

published in

Molecular Informatics

1 reference

12 August 2017

volume

31

1 reference

12 August 2017

issue

11-12

1 reference

12 August 2017

page(s)

847-855

1 reference

Origin and evolution of high throughput screening

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Is there a difference between leads and drugs? A historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Current trends in lead discovery: are we looking for the appropriate properties?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

COMPOUND PROPERTIES AND DRUG QUALITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

A comparison of physiochemical property profiles of development and marketed oral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Physiochemical drug properties associated with in vivo toxicological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Natural products as sources of new drugs over the last 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Red wine consumption improves insulin resistance but not endothelial function in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Beverage use and risk for kidney stones in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Potential mechanisms of cancer chemoprevention by anthocyanins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Cheminformatic tools for medicinal chemists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Molecular properties that influence the oral bioavailability of drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Estimation of the aqueous solubility I: application to organic nonelectrolytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Influence of juice pressing conditions on polyphenols, antioxidants, and varietal aroma of Sauvignon blanc microferments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Influence of grape-harvesting steps on varietal thiol aromas in Sauvignon blanc wines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Cyclooxygenase inhibitory and antioxidant compounds from crabapple fruits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Relative inhibition of lipid peroxidation, cyclooxygenase enzymes, and human tumor cell proliferation by natural food colors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

The identification of novel PLC-gamma inhibitors using virtual high throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

The effect of PLC-γ2 inhibitors on the growth of human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Nonleadlikeness and leadlikeness in biochemical screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Fragment-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Fragment-Based Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Characteristics of known drug space. Natural products, their derivatives and synthetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMINF.201200103

Reactive compounds and in vitro false positives in HTS

21 January 2018

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/MINF.201200103

The basis for the chemopreventive action of resveratrol.

8 April 2023

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/MINF.201200103

Resveratrol, a remarkable inhibitor of ribonucleotide reductase

8 April 2023

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/MINF.201200103

The continuing evolution of the drug discovery process in the pharmaceutical industry

8 April 2023

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/MINF.201200103

Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat

8 April 2023

1 reference

https://opencitations.net/index/coci/api/v1/references/10.1002/MINF.201200103

8 April 2023

Identifiers

DOI

10.1002/MINF.201200103

1 reference

12 August 2017

1 reference